ResMed takes action against US firm in patent battle
14 October, 2002 by Melissa TrudingerAustralian sleep apnoea devices company ResMed has filed a lawsuit against US-based Respironics, claiming that several Respironics products infringe on ResMed patents.
Benitec, Ozgene team up to build a better rat model
11 October, 2002 by Pete YoungA potentially lucrative bid to provide the drug industry with improved testing capabilities on animal models has been launched by two Australian biotechs.
Cardia restructures with a little help from Big Pharma
11 October, 2002 by Iain ScottMelbourne-based company Cardia Technologies has wrapped its medical biotech projects into a new wholly-owned subsidiary company, Big Pharma Ltd.
Acrux restructures licensing deal
10 October, 2002 by Graeme O'NeillMelbourne pharmaceutical company Acrux has done an IP swap with Soltec Research that will allow both companies to further their development of transdermal and topical therapeutics.
New horizons for pSivida
09 October, 2002 by Pete YoungThe announcement that pSivida's porous silicon technology, BioSilicon, has shown it can perform diagnostic tests when applied as a skin patch opens up new revenue horizons for the Perth biotech.
Sirtex wins humanitarian device award
09 October, 2002 by Melissa TrudingerSydney-based company Sirtex Medical has been awarded the Humanitarian Benefit Device of the Year 2002 for its SIR-Spheres liver cancer treatment by Frost and Sullivan, a US-based market consulting and analyst group.
Clinical Cell Culture turning heads in the US
08 October, 2002 by Pete YoungPerth skin replacement company Clinical Cell Culture (C3) has caught the attention of Nasdaq-listed US artificial skin specialist Integra Life Sciences Corporation.
Devices of industry
04 October, 2002 by Melissa TrudingerOutside the industry, the words 'Australian biotechnology' immediately conjure up three names in particular -- CSL, Cochlear and ResMed. The irony is that none of these companies is strictly a biotechnology company.
BTF boosted by VC funding
03 October, 2002 by Pete YoungA young biotech company founded by two Macquarie University scientists has attracted $2 million in funding from venture capital firm Nanyang Ventures.
Cellestis promises Danish deal will provide better TB diagnosis
03 October, 2002 by Iain ScottMelbourne-based company Cellestis has signed an agreement with Danish company Statens Serum Institut that it said signals a new era in tuberculosis testing and research.
Proteome System teams with Charles River to form contract service
03 October, 2002 by Iain ScottSydney-based company Proteome Systems has teamed up with big US services company Charles River Laboratories to create a new joint venture company, Charles River Proteomics Services.
How a giant 'jelly doughnut' could get the good oil
02 October, 2002 by Graeme O'NeillThe world is not running out of oil, according to Montana State University microbiologist Prof Bill Costerton -- it's just too difficult to get the vast amounts of oil that remain in the ground after oilfields expire.
Biotech breathes life into ethanol R&D
01 October, 2002 by Graeme O'NeillOil prices are again pushing $US30 a barrel, glaciers are melting, and cuckoos are announcing spring in Europe's woodlands some 16 days earlier than they did half a century ago. And not for the first time since the OPEC-engineered oil supply crisis of the mid-1970s, an Australian government is talking up the need to develop a local fuel ethanol industry.
Ovarian xenotransplantation could offer hope for rare species
27 September, 2002 by Melissa TrudingerXenotransplantation of ovarian tissue from endangered species may allow zoologists and conservationists to propagate endangered animals, according to a paper published today in the journal Science.
Genesis beefs up strategic development with new hiring
27 September, 2002 by Graeme O'NeillNew Zealand's Genesis Research and Development Corporation has persuaded long-serving director Dr Douglas Williams to join the company as head of its new strategic development unit, as part of its plan to make hay while it waits for the sun to rise again on the biotech industry.
